Advanced Oncology Certified Nurse Practitioner (AOCNP) Certification Practice Test

The estrogen receptor (ER) signaling pathway is primarily involved in the development of breast cancer because many breast cancer cells rely on estrogen for growth and proliferation. Approximately 70% of breast cancers are classified as estrogen receptor-positive, meaning they grow in response to estrogen. This makes the pathway crucial not only in the pathogenesis of breast cancer but also in the treatment strategies employed, such as using anti-estrogens like tamoxifen or aromatase inhibitors to block estrogen's effects and slow down the growth of these tumors.

While other pathways, such as the MAPK pathway and the PI3K/Akt pathway, can also play roles in tumorigenesis and contribute to the complexity of breast cancer biology, they are not the primary drivers as identified through extensive research. The apoptosis pathway focuses on programmed cell death, which is relevant to cancer progression but does not directly drive the development of breast cancer as the ER signaling pathway does. The correlation between estrogen levels and breast cancer incidence underscores the significant impact of the ER signaling pathway in this disease.